Trial of Memantine for Cognitive Impairment in Multiple Sclerosis

Phase 2/3 Completed 82 enrolled Oregon Health and Science University Forest Laboratories · collab MS-Hub Seattle · collab University of Southern California · collab University of Texas Southwestern Medical Center · collab

RandomizedParallel-groupDouble-blindTreatment

Summary

This study is designed to determine whether memantine is an effective treatment for memory and cognitive problems associated with multiple sclerosis when compared to placebo.

Timeline

Start: 2004-04
Primary completion: 2009-01
Completion: 2009-01

Outcome

Missed primary endpoint

paper The differences between the groups on the change on the PASAT (placebo-memantine = 0.0 correct responses, 95% CI 3.4, 3.4; p = 0.9) PMID 20483885 ↗

paper and on CVLT-II LDFR (placebo-memantine =-0.6 words, 95% CI -2.1, 0.8; p = 0.4) PMID 20483885 ↗

paper Memantine 10 mg twice a day does not improve CP in subjects with MS PMID 20483885 ↗

Publications

Lovera JF, Frohman E, Brown TR, Bandari D, Nguyen L, Yadav V, Stuve O, Karman J, Bogardus K, Heimburger G, Cua L, Remingon G, Fowler J, Monahan T, Kilcup S, Courtney Y, McAleenan J, Butler K, Wild K, Whitham R, Bourdette D. Memantine for cognitive impairment in multiple sclerosis: a randomized placebo-controlled trial. Mult Scler. 2010 Jun;16(6):715-23. doi: 10.1177/1352458510367662. Epub 2010 May 18.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Memantine	Unknown	20 mg	—